Arvinas, Palleon founders extend the reach of targeted degraders

How ENDTACs and LYTACs expand the reach of targeted protein degradation

A study from Arvinas founder Craig Crews is the second report in as many months of a technology geared to degrade extracellular proteins. The platforms open up new territory for targeted degradation therapies, on the heels of the modality's clinical debut.

In a Thursday ACS Central Science article, Crews' lab at Yale University introduced

Read the full 532 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE